The study started using a QD dose escalation scheme, and the occurrence of dose-limiting liver toxicity as evidenced by the Grade 3 and Grade 4 elevation of transaminases, AP, or γ-GT at 120 mg led to the identification of 80 mg as the MTD in the QD schedule. The gene discussed is DHCR7-DT; the disease is hepatotoxicity.